. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: J Allergy Clin Immunol. 2021 Jan 22;148(1):256–261.e2. doi: 10.1016/j.jaci.2020.12.629

Table 1.

Key features of patients’ clinical disease and immunological workup.

Demographics	Pt. 1	Pt. 2
Y.O.A. (as of 10/2019)	15	10
Sex	male	female
Ethnic background of parents	caucasian	caucasian
Primary Diagnosis	Chronic mucocutaneous candidiasis, recurrent skin rash, pityriasis lichenoides	Chronic mucocutaneous candidiasis
Age at onset/presentation	2 months	1 year
Secondary diagnoses	Moniliasis episodes recur as soon as prophylaxis is interrupted. Experiences cutaneous rash at extremities, neck and intertriginous skin.	Chronic intertrigo, folliculitis
Lymphadenenopathy	no	no
Splenomegaly	no	no
Hematologic abnormalities	no	no
Malignancy/lymphoma	no	^ no
Autoimmunity or autoinflammatory disease	no	no
Immunodeficiency or susceptibility to infection	yes, chronic mucocutaneous candidiasis, recurrent/destructive Otitis Media	yes, chronic mucocutaneous candidiasis
Liver abnormalities	no	no
Antibody Abnormalities	no	no
Lung involvement	no	no
Height (percentile)	10–25th	25–50th
Weight (percentile)	50th	25–50th
Other significant symptoms	no	no
Immunological Workup
Quantitative Immunoglobulins (mg/dl)	IgG: 1260 (876–2197) IgA: 73 (108–447) IgM: 75 (75–448) IgG1: 758 (547–1474) IgG2: 363 (77–706) IgG3: 35 (36–238) IgE: 686 ng/ml	IgG: 1490 (431–1803) IgM: 87 (126–449) IgA: 138 (45–164)
CBC with differential	WBC: 10800 (4500–13000) ANC: 6000 (1500–8000) ALC: 2800 (1400–4500) Eo: 1000 (44– 400) Hb: 11.4 (11– 16) Plt: 338000 (150000– 400000)	WBC: 8500 (4500–13800), ANC: 2700 (1500–8600), ALC 4900 (1800–5600), Eo: 100, Hb 9.6 (11–14), Plt 335000 (182000–564000)
Flow Cytometry	CD3: 50%(47–76) CD3+4: 33% (23–48) CD3+8: 27% (25–50) CD19: 30% (14–44) CD16+56: 22% (4–23)	CD3⁺: 50% (55–88), CD3 ⁺4⁺: 43% (24–50), CD3⁺8⁺:16% (17–42), CD19 ⁺:14% (7–22), CD3⁻16/56⁺:14% (4–29)